Published in Vasc Health Risk Manag on January 01, 2007
Global and societal implications of the diabetes epidemic. Nature (2001) 25.18
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Standards of medical care in diabetes--2006. Diabetes Care (2006) 9.56
Roles of PPARs in health and disease. Nature (2000) 5.87
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation (2002) 3.96
Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care (2006) 2.98
Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab (2004) 2.36
Thiazolidinediones: an update. Lancet (2000) 2.25
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes (2004) 1.92
Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C. Diabetes Technol Ther (2003) 1.46
The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J Mol Med (Berl) (2001) 1.36
Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs (1998) 1.28
Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol (2003) 1.22
Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes (2002) 1.19
Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation (2003) 1.19
Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs (2002) 1.07
Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care (2004) 1.03
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med (2000) 1.00
Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem (2005) 0.97
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab (2006) 0.93
Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway. Atherosclerosis (2005) 0.92
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract (2004) 0.89
Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance. Clin Lab (2004) 0.87
Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens (2003) 0.86
Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. Acta Diabetol (2004) 0.85
Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism (2006) 0.83
Stimulation by proinsulin of expression of plasminogen activator inhibitor type-I in endothelial cells. Diabetes (1992) 0.82
Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract (2004) 0.82
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab (2006) 0.81
Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy. Clin Ther (2004) 0.79
Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients. Chin Med J (Engl) (2003) 0.79
An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Curr Med Res Opin (2002) 0.78
Rosiglitazone/Metformin. Drugs (2005) 0.77
Clinical review of glimepiride. Expert Opin Pharmacother (2001) 0.77
Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study. Am J Manag Care (2005) 0.76
Addition of rosiglitazone to glimepirid and metformin combination therapy in type 2 diabetes. Endocr J (2004) 0.76
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet (2012) 3.48
Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3. J Diabetes Sci Technol (2010) 2.48
Clinical assessment of the accuracy of blood glucose measurement devices. Curr Med Res Opin (2012) 2.18
Accuracy evaluation of five blood glucose monitoring systems obtained from the pharmacy: a European multicenter study with 453 subjects. Diabetes Technol Ther (2011) 1.89
Analysis of the environmental impact of insulin infusion sets based on loss of resources with waste. J Diabetes Sci Technol (2011) 1.74
Dynamic electrochemistry corrects for hematocrit interference on blood glucose determinations with patient self-measurement devices. J Diabetes Sci Technol (2011) 1.61
Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol (2005) 1.60
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care (2013) 1.55
Impact of posture and fixation technique on impedance spectroscopy used for continuous and noninvasive glucose monitoring. Diabetes Technol Ther (2004) 1.53
High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther (2006) 1.48
Determination of nitrotyrosine concentrations in plasma samples of diabetes mellitus patients by four different immunoassays leads to contradictive results and disqualifies the majority of the tests. Clin Chem Lab Med (2009) 1.42
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol (2007) 1.38
Development and validation of a new measure to evaluate psychological resistance to insulin treatment. Diabetes Care (2007) 1.34
Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care (2004) 1.26
Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications (2006) 1.21
Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide (2003) 1.20
Hematocrit interference of blood glucose meters for patient self-measurement. J Diabetes Sci Technol (2013) 1.18
Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug Deliv (2005) 1.08
Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther (2004) 1.03
Blood glucose meters employing dynamic electrochemistry are stable against hematocrit interference in a laboratory setting. J Diabetes Sci Technol (2013) 1.01
Determination of hematocrit interference in blood samples derived from patients with different blood glucose concentrations. J Diabetes Sci Technol (2013) 1.01
High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. J Diabetes Sci Technol (2010) 1.00
Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk. Clin Lab (2005) 0.99
Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health (2005) 0.98
Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab (2003) 0.97
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res (2008) 0.97
Evaluation of dexterity in insulin-treated patients with type 1 and type 2 diabetes mellitus. J Diabetes Sci Technol (2011) 0.96
Evaluation of CGMS during rapid blood glucose changes in patients with type 1 diabetes. Diabetes Technol Ther (2006) 0.93
Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. J Diabetes Sci Technol (2011) 0.92
Comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skills. J Diabetes Sci Technol (2012) 0.92
The precision study: examining the inter- and intra-assay variability of replicate measurements of BGStar, iBGStar and 12 other blood glucose monitors. Expert Opin Med Diagn (2013) 0.92
Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus. Clin Chem Lab Med (2006) 0.91
Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects. Expert Opin Pharmacother (2007) 0.91
The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus. Diabetes Technol Ther (2006) 0.90
Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev Cardiovasc Ther (2006) 0.89
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovasc Diabetol (2011) 0.88
Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance. Clin Lab (2004) 0.87
The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther (2008) 0.87
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther (2011) 0.87
Peripheral leptin levels in narcoleptic patients. Diabetes Technol Ther (2007) 0.86
Assessment of the mixing efficiency of neutral protamine Hagedorn cartridges. J Diabetes Sci Technol (2010) 0.85
IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design. Diabetes Technol Ther (2005) 0.85
Effect of insulin glulisine on microvascular blood flow and endothelial function in the postprandial state. Diabetes Care (2008) 0.84
Increased arterial augmentation and augmentation index as surrogate parameters for arteriosclerosis in subjects with diabetes mellitus and nondiabetic subjects with cardiovascular disease. J Diabetes Sci Technol (2007) 0.84
Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study. Diabetes Technol Ther (2010) 0.83
Physicochemical features of ultra-high viscosity alginates. Carbohydr Res (2009) 0.83
Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism (2006) 0.83
In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment. J Diabetes Sci Technol (2012) 0.82
Dapagliflozin, an SGLT2 inhibitor, for diabetes. Lancet (2010) 0.82
Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus. Gynecol Endocrinol (2007) 0.81
Clinical and laboratory evaluation of specific chemiluminescence assays for intact and total proinsulin. Clin Chem Lab Med (2003) 0.81
Endothelial function and arterial stiffness in uncomplicated type 1 diabetes and healthy controls and the impact of insulin on these parameters during an euglycemic clamp. J Diabetes Sci Technol (2007) 0.81
Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics--results from a German observational study. BMC Psychiatry (2011) 0.80
No effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: a randomized open-label study. J Diabetes Sci Technol (2012) 0.80
A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic inflammation in type 2 diabetes mellitus. Clin Lab (2008) 0.79
The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. J Diabetes Sci Technol (2011) 0.79
C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients. Exp Diabetes Res (2008) 0.79
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study. J Diabetes Sci Technol (2011) 0.79
Cross-sectional investigation on the accuracy of alternate site glucose testing using the Soft-Sense glucose meter. Swiss Med Wkly (2002) 0.79
Investigation of insulin resistance in narcoleptic patients: dependent or independent of body mass index? Neuropsychiatr Dis Treat (2011) 0.78
Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality. Expert Opin Pharmacother (2006) 0.78
Evaluation of a new fully automated one-step C-peptide chemiluminescence assay (LIAISON C-Peptid). Clin Lab (2003) 0.78
Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study. Cardiovasc Diabetol (2013) 0.78
Development and validation of a rapid and reliable method for TPMT genotyping using real-time PCR. Clin Lab (2012) 0.78
IRIS II Study: Sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance. Diabetes Technol Ther (2004) 0.78
Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study. J Diabetes Sci Technol (2009) 0.78
Patient device assessment evaluation of two insulin injection devices in a mixed cohort of insulin-treated patients with type 1 or type 2 diabetes mellitus. Curr Med Res Opin (2012) 0.78
Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions. Diabetes Technol Ther (2009) 0.77
Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. J Diabetes Sci Technol (2007) 0.77
Laboratory evaluation of a new lateral-flow-based point-of-care rapid test for assessment of chronic systemic inflammation. J Diabetes Sci Technol (2010) 0.77
The beta-specific protein kinase C inhibitor ruboxistaurin (LY333531) suppresses glucose-induced adhesion of human monocytes to endothelial cells in vitro. J Diabetes Sci Technol (2007) 0.77
Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA study. Diab Vasc Dis Res (2010) 0.77
Resolution of adiponectin oligomers in human plasma using free flow electrophoresis. Arch Physiol Biochem (2009) 0.76
Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study. Atherosclerosis (2008) 0.76
Evaluation of the effects of insufficient blood volume samples on the performance of blood glucose self-test meters. J Diabetes Sci Technol (2013) 0.75
Self-monitoring of blood glucose levels requires intensive training for use of meters to obtain reliable and clinically relevant measurements. J Diabetes Sci Technol (2007) 0.75
Response to Jungheim and Koschinsky. Diabetes Care (2002) 0.75
Downregulation of the proinflammatory state of circulating mononuclear cells by short-term treatment with pioglitazone in patients with type 2 diabetes mellitus and coronary artery disease. PPAR Res (2011) 0.75
Pioglitazone improves metabolic markers in patients with type 2 diabetes independently from physical activities: results from the IRIS III study. J Diabetes Sci Technol (2008) 0.75
Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren Study. Nephron Extra (2012) 0.75
Elevated peripheral visfatin levels in narcoleptic patients. PLoS One (2008) 0.75
New tricks by an old dog. Exp Diabetes Res (2008) 0.75
Assessment for ease of use and preference of a new prefilled insulin pen (FlexTouch Degludec U100/U200) versus the SoloSTAR insulin pen by patients with diabetes and healthcare professionals. Expert Opin Drug Deliv (2014) 0.75
Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study. Clin Lab (2009) 0.75
Effect of C-peptide on glucose metabolism in patients with type 1 diabetes. Diabetes Care (2002) 0.75
Evaluation of SET--a new device for the measurement of pain perception in comparison to standard measures of diabetic neuropathy. Diabetes Technol Ther (2004) 0.75
Relaxin expression correlates significantly with serum changes in VEGF in response to antidiabetic treatment in male patients with type 2 diabetes mellitus. Clin Lab (2007) 0.75
Development and validation of a high-throughput screening method for two polymorphisms in the serotonin transporter gene. Mol Diagn Ther (2009) 0.75